

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 July 2023 (27.07.2023)



(10) International Publication Number
WO 2023/139506 A1

(51) International Patent Classification:

A61K 45/06 (2006.01) A61K 31/53 (2006.01)
A61P 9/12 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2023/050444

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

19 January 2023 (19.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/300,967 19 January 2022 (19.01.2022) US
63/400,301 23 August 2022 (23.08.2022) US

(71) Applicants: MINERALYS THERAPEUTICS, INC.
[US/US]; 150 N. Radnor Chester Rd, Suite F200, Radnor, Pennsylvania 19087 (US). MITSUBISHI TANABE PHARMA CORPORATION [JP/JP]; 3-2-10, Doshomachi, Chuo-ku, Osaka-shi, Osaka 5418505 (JP).

(72) Inventors: RODMAN, David; 150 N. Radnor Chester Rd, Suite F200, Radnor, Pennsylvania 19087 (US). SLINGSBY, Brian Taylor; 150 N. Radnor Chester Rd, Suite F200, Radnor, Pennsylvania 19087 (US). CONGLETON, Jon; 150 N. Radnor Chester Rd, Suite F200, Radnor, Pennsylvania 19087 (US). SHIMIZU, Hidetoshi; 3-2-10, Doshomachi, Chuo-ku, Osaka-shi, Osaka 5418505 (JP). OTA, Yoshiyasu; 3-2-10, Doshomachi, Chuo-ku, Osaka-shi, Osaka 5418505 (JP). ORIHASHI, Madori; 3-2-10, Doshomachi, Chuo-ku, Osaka-shi, Osaka 5418505 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: METHODS OF TREATING HYPERTENSION BY PERIODIC SUPPRESSION OF ALDOSTERONE SYNTHASE

(57) Abstract: This invention provides method of treating hypertension in a hypertensive subject, the method comprising administering to the subject a CYP 11 β 2 beta hydroxylase inhibitor once or twice per day in an amount sufficient to inhibit 50% or more of CYP 11 β 2 beta hydroxylase's activity for 40-60% of a 24-hour period to thereby treat hypertension in the hypertensive subject.

WO 2023/139506 A1